Fiona uses cutting edge genome editing CRISPR technology to carry out genome-wide synthetic lethal screens in order to identify potential novel oncogenic therapeutic targets.

Using her background in molecular biology and high throughput screening, Fiona aims to leverage large scale, genome wide screens to develop effective anti-cancer strategies.

Funded through the Centre for Therapeutic Target Validation (CTTV), our current research uses CRISPR-Cas9 technology to define synthetic-lethal dependences in cancer cell lines. This work aims to find new oncology drug targets.